Outcomes of Additional Treatment for Patients With Infiltrative Hepatocellular Carcinoma Lance L. Stein, MD, Marty T. Sellers, MD, MPH Clinical Gastroenterology and Hepatology Volume 11, Issue 12, (December 2013) DOI: 10.1016/j.cgh.2013.06.029 Copyright © 2013 AGA Institute Terms and Conditions
Figure 1 Survival of iHCC patients undergoing DEB-TACE vs DEB-TACE + sorafenib (Child–Pugh A and B). Clinical Gastroenterology and Hepatology 2013 11, DOI: (10.1016/j.cgh.2013.06.029) Copyright © 2013 AGA Institute Terms and Conditions